EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR) mutation is recognized as one of the most important targets in patients with advanced non–small cell lung cancer (NSCLC), and EGFR tyrosine kinase inhibitor (EGFR‐TKI) administration is the standard treatment for NSCLC patients carrying EGFR sensitive mutations.